Summary
To evaluate the usefulness of recently proposed schemes of classification for systemic sclerosis an extensive cross-sectional study of a series of 164 consecutive patients with long-term systemic sclerosis was undertaken. There were 47 cases of proximal sclerosis, 93 of distal sclerosis and 24 of complete CREST syndrome. The study included clinical, visceral, immunological and follow-up data. In addition, a quantitative clinical score was calculated for each patient, thus providing indications for prognosis. Data were expressed according to three conventional systems of classification: The ARA system, the diffuse versus limited systemic sclerosis system and the early cutaneous involvement system. The most reliable indications of severe outcome were: proximal sclerosis, trunk skin involvement, presence of anti Scl 70 autoantibody, pulmonary and/or heart involvement and age. Diagnosis and prognosis were not generated by the same items. Prognosis indicators proved more accurate for groups than for individuals. Mortality was 1 death per 149 patient X years of follow-up from diagnosis. We conclude that the ARA criteria for classification should be recognized as a standard, but patients with complete CREST syndrome should be included in the distal group. Other systems of classification, principally 2-way versus 3-way criteria, allow different subsets of patients that correlate with prognosis and the severity of the disease, and could be used for therapeutic purposes.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Tuffanelli, D.L., Winkelmann, R.K. Systemic scleroderma. A clinical study of 727 cases. Arch Dermatol 1961, 84, 359–371.
Tuffanelli, D.L., Winkelmann, R.K. Diffuse systemic scleroderma. A comparison with acrosclerosis. Ann Intern Med 1962, 57, 198–203.
Barnett, A.J., Coventry, D.A. Scleroderma: 1. clinical features, course of illness and response to treatment in 61 cases. Med J Aust 1969, 1, 992–1001.
Rowell, N.R. The prognosis of systemic sclerosis. Br J Dermatol 1976, 95, 57–60.
Barnett, A.J. Scleroderma (progressive systemic sclerosis): progress and course based on a personal series of 118 cases. Med J Aust 1978, 2, 129–134.
Livingston, J.Z., Scott, T.E., Wigley, F.M., Anhalt, G.J., Bias, W.B., McLean, R.H., Hochberg, M.C. Systemic sclerosis (scleroderma): clinical, genetic, and serologic subsets. J Rheumatol 1984, 14, 512–518.
Cassani, F., Tosti, A., Bianchi, F.B., Fusconi, M., Selleri, L., Baffoni, L., Veronesi, S., Volta, U., Lenzi, M., Pisi, E. Clinical subsets of scleroderma: relevance of fluorescent and precipitating anti-nuclear antibodies. Clin Exp Rheum 1987, 5, 23–28.
Masi, A., D'Angelo, W.A. Epidemiology of fatal systemic sclerosis (diffuse scleroderma) A 15-year survey in Baltimore. Ann Intern Med 1967, 66, 870–875.
Medsger, T.A., Masi, A.T. Epidemiology of systemic sclerosis (scleroderma) Ann Intern Med 1971, 74, 714–721.
Medsger, T.A., Masi, A.T., Rodnan, G.P., Benedek, T.G., Robinson, H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971, 75, 369–376.
Giordano, M., Valentini, G., Migliaresi, S., Picillo, V., Vatti, M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986, 13, 911–916.
Barnett, A.J., Miller, M.H., Littlejohn, G.O. A survival study of patients with scleroderma diagnosed over 30 years (1953–1983): The value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 1988, 15, 276–283.
Le Roy, E.C., Black, C., Fleischmajer, R., Jablonska, S., Krieg, T., Medsger, T.A. In Rowell, N., Wollheim, F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15, 202–205.
Masi, A.T. Classification of systemic sclerosis (scleroderma): Relationship of cutaneous subgroups in early disease to outcome and serologic reactivity. J Rheumatol 1988, 15, 894–898.
Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23, 581–590.
Maricq, H.R., Le Roy, E.C., D'Angelo, W.A., Medsger, T.A.Jr., Rodnan, G.P., Sharp, G.C., Wolfe, J.F. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 1980, 23, 183–189.
Chisholm, D.M., Mason, D.K. Labial salivary gland biopsy in Sjögren's disease. J Clin Pathol 1968, 21, 656–660.
Hughes, P., Holt, S., Rowell, N.R., Dodd, J. Thymus — dependent (T) lymphocyte deficiency in progressive systemic sclerosis. Br J Dermatol 1976, 95, 469–473.
Hughes, P., Holt, S., Rowell, N.R., Allonby, I.D., Dodd, J.K. The relationship of defective cell-mediated immunity to visceral disease in systemic sclerosis. Clin Exp Immunol 1977, 28, 233–240.
Hughes, P., Gelsthorpe, K., Doughty, R.W., Rowell, N.R., Rosenthal, F.D., Sneddon, I.B. The association of HLA-B8 with visceral disease in systemic sclerosis. Clin Exp Immunol 1978, 31, 351–356.
Greaves, M., Malia, R.G., Milfordward, A., Moult, J., Holt, C.M., Lindsey, N., Hughes, P., Goodfield, M., Rowell, N.R. Elevated von Willebrand factor antigen in systemic sclerosis: relationship to visceral disease. Br J Rheumatol 1988, 27, 281–285.
Johanet, C., Agostini, M.M., Vayssairat, M., Abuaf, N. Autoanticorps anti-Scl 70 et anti-centromere. Marqueurs biologiques de 2 variétés différentes de sclérodermie systémique. Press Med 1989, 18, 207–211.
Fritzler, M.J., Kinsella, T.D., Garbutt, E. The CREST syndrome: A distinct serologic entity with anticentromere antibodies. Am J Med 1980, 69, 521–526.
Tan, E.M., Rodnan, G.P., Garcia, I., Moroi, Y., Fritzler, M.J., Peebles, C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Arthritis Rheum 1980, 23, 617–625.
Kallenberg, C.G.M., Pastoor, G.W., Wouda, A.A., The T.H. Antinuclear antibodies in patients with Raynaud's phenomenon: Clinical significance of anticentromere antibodies. Ann Rheum Dis 1982, 41, 382–387.
Mc Carty, G.A., Rice, J.R., Bembe, M.L., Barada, F.A. Anticentromere antibody. Clinical correlations and association with favourable prognosis in patients with scleroderma variants. Arthritis Rheum 1983, 26, 1–7.
Jarzabek-Chorzelska, M., Blaszcyk, M., Jablonska, S., Chorzelski, T., Kumar, V., Beutner, E.H. Scl 70 antibody — a specific marker of systemic sclerosis. Br J Dermatol 1986, 115, 393–401.
Reimer, G., Steen, V.D., Penning, C.A., Medsger, T.A., Tan, E.M. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1988, 31, 525–532.
Weiner, E.S., Earnshaw, W.C., Senecal, J.L., Bordwell, B., Johnson, P., Rothfield, N.F. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum 1988, 31, 378–385.
Steen, V.D., Powell, D.L., Medsger, T.A.Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988, 31, 196–203.
Peters-Golden, M., Wise, R.A., Hochberg, M., Stevens, M.B., Wigley, F.M. Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. Am J Med 1984, 77, 1027–1034.
Kostis, J.B., Seibold, J.R., Turkevich, D., Masi, A.T., Grau, R.G., Medsger, T.A.Jr., Steen, V.D., Clements, P.J., Szydlo, L., D'Angelo, W.A. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med 1988, 84, 1007–1015.
Steen, V.D., Ziegler, G.L., Rodnan, G.P., Medsger, T.A. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 1984, 27, 125–131.
Giordano, M. The CREST acronym and some related problems. Arthritis Rheum 1985, 28, 359.
Rodnan, G.P., Medsger, T.A.Jr., Buckingham, R.B. Progressive systemic sclerosis — CREST syndrome: Observations on natural history and late complications in 90 patients. Arthritis Rheum 1975, 18, 423 (abstract).
Priollet, P., Vayssairat, M., Housset, E. How to classify Raynaud's phenomenon. Long term follow-up study of 73 cases. Am J Med 1987, 83, 494–498.
Crown, S. Visceral scleroderma without skin involvement. Br Med J 1961, 2, 1541–1543.
Farmer, R.G., Gifford, R.W., Hines, E.A. Raynaud's disease with sclerodactylia. A follow-up study of seventy-one patients. Circulation 1961, 23, 13–15.
Rodnan, G.P., Fennell, R.H.Jr. Progressive systemic sclerosis sine scleroderma. JAMA 1962, 180, 665–670.
Barr, W.G., Robinson, J.A. Systemic sclerosis and digital gangrene without scleroderma. J Rheumatol 1988, 15, 875–877.
Kallenberg, C.G.M., Wouda, A.A., Hoet, M.H., Van Venrooij, W.J. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six-year follow-up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988, 47, 634–641.
Fitzgerald, O., Hess, E.V., O'Connor, G.T., Spencer-Green, G. Prospective study of the evolution of Raynaud's phenomenon. Am J Med 1988, 84: 718–726.
Van der Linden, S.M., Tugwell, P. Pitfalls in assessment of prognosis. Weak study designs are liable to bias. J Rheumatol 1988, 15, 725–727.
Velayos, E.E., Masi, A.T., Stevens, M.B., Shulman, L.E. The “CREST” syndrome. Comparison with systemic sclerosis (scleroderma). Arch Intern Med 1979, 139, 1240–1244.
Salerni, R., Rodnan, G.P., Leon, D.F., Shaver, J.A. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (Scleroderma). Ann Intern Med 1977, 86, 394–399.
Stupi, A.M., Steen, V.D., Owens, G.R., Barnes, L., Rodnan, G.P., Medsger, T.A.Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986, 29, 515–524.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vayssairat, M., Baudot, N., Abuaf, N. et al. Long-term follow-up study of 164 patients with definite systemic sclerosis: Classification considerations. Clin Rheumatol 11, 356–363 (1992). https://doi.org/10.1007/BF02207193
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02207193